ReachMD
Project Oncology®Episodes
Episodes of Project Oncology®
Mark All
Search Episodes...
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Justin Arnall, PharmD, BCOP, CPP Guest: Jerry L. Spivak MD, MACP While managing patients with myelofibrosis, there are certain indications that it may be time to switch thera
Guest: Justin Arnall, PharmD, BCOP, CPP Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jerry L. Spivak MD, MACP After assessing the severity of anemia in patients with myelofibrosis, it’s important to work with them to se
Guest: Justin Arnall, PharmD, BCOP, CPP Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jerry L. Spivak MD, MACP After assessing the severity of anemia in patients with myelofibrosis, it’s important to work with them to se
Host: Jennifer Caudle, DO Guest: Jason Tremblay Due to a high prevalence of anemia in myelofibrosis, significant challenges could occur when diagnosing patients. But making a timely and accurate diagnosis is key, along with en
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Prithviraj Bose, MD Normally, when a patient is newly diagnosed with myelofibrosis, the anemia is from the disease. And it’s important to treat these patients with an individual
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Prithviraj Bose, MD Normally, when a patient is newly diagnosed with myelofibrosis, the anemia is from the disease. And it’s important to treat these patients with an individual
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Prithviraj Bose, MD Normally, when a patient is newly diagnosed with myelofibrosis, the anemia is from the disease. And it’s important to treat these patients with an individual
Host: Jennifer Caudle, DO Guest: Jason Tremblay Due to a high prevalence of anemia in myelofibrosis, significant challenges could occur when diagnosing patients. But making a timely and accurate diagnosis is key, along with en
Host: Jennifer Caudle, DO Guest: Jason Tremblay Myelofibrosis is a heterogeneous disease and different hematologic manifestations, like anemia and thrombocytopenia, are variable based on the patients themselves. It might even
Host: Jennifer Caudle, DO Guest: Jason Tremblay Myelofibrosis is a heterogeneous disease and different hematologic manifestations, like anemia and thrombocytopenia, are variable based on the patients themselves. It might even
Guest: Matthew Lunning, DO, FACP It’s not uncommon for patients with B-cell lymphoma to have relapsed or refractory disease, making it essential to know how to approach their second-line treatment. Unfortunately, many challenges a
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Tara Graff, DO, MS The therapeutic landscape for relapsed or refractory B-cell lymphoma has greatly evolved in the past several years, with CAR T-cell therapy and personalized ca
Host: Jennifer Caudle, DO Guest: Sarah Rutherford, MD Due to its strong response rates and manageable adverse events, CAR T-cell therapy is now considered the standard-of-care treatment for B-cell lymphomas in the second-line
Host: Jennifer Caudle, DO Guest: Sarah Rutherford, MD Due to its strong response rates and manageable adverse events, CAR T-cell therapy is now considered the standard-of-care treatment for B-cell lymphomas in the second-line
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Tara Graff, DO, MS The therapeutic landscape for relapsed or refractory B-cell lymphoma has greatly evolved in the past several years, with CAR T-cell therapy and personalized ca
Guest: Matthew Lunning, DO, FACP It’s not uncommon for patients with B-cell lymphoma to have relapsed or refractory disease, making it essential to know how to approach their second-line treatment. Unfortunately, many challenges a
Guest: Alan Bryce, MD Lutetium-177and radium-223 have both been shown to significantly improve survival in patients with metastatic castration-resistant prostate cancer, but how do these treatment options compare? Find out with Dr
Guest: Alan Bryce, MD Lutetium-177and radium-223 have both been shown to significantly improve survival in patients with metastatic castration-resistant prostate cancer, but how do these treatment options compare? Find out with Dr
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Neeraj Agarwal, MD, FASCO TALAPRO-2 was a recent phase 3 study conducted in the first-line metastatic castration-resistant prostate cancer (mCRPC) setting. Patients were randomiz
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Neeraj Agarwal, MD, FASCO TALAPRO-2 was a recent phase 3 study conducted in the first-line metastatic castration-resistant prostate cancer (mCRPC) setting. Patients were randomiz
Host: Rishi Sekar, MD A recent study sought to investigate why there are disparities in mortality as well as access and participation in clinical trials among vulnerable prostate cancer populations. According to the findings, coun
Host: Rishi Sekar, MD A recent study sought to investigate why there are disparities in mortality as well as access and participation in clinical trials among vulnerable prostate cancer populations. According to the findings, coun
Host: Jacob Sands, MD Guest: Aakesh Desai, MD, MPH According to research featured at the 2023 ASCO Annual Meeting, novel immune checkpoint targets have the potential to inform drug development and combination strategies to opt
Host: Zachery Reichert MD, PhD If hormonal therapies are not working for prostate cancer patients, chemotherapy may be a reliable alternative based on findings from a recent study. In fact, out of the 70 percent of patients who ha
Host: Zachery Reichert MD, PhD If hormonal therapies are not working for prostate cancer patients, chemotherapy may be a reliable alternative based on findings from a recent study. In fact, out of the 70 percent of patients who ha
Join Podchaser to...
- Rate podcasts and episodes
- Follow podcasts and creators
- Create podcast and episode lists
- & much more
Unlock more with Podchaser Pro
- Audience Insights
- Contact Information
- Demographics
- Charts
- Sponsor History
- and More!
- Account
- Register
- Log In
- Find Friends
- Resources
- Help Center
- Blog
- API
Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More
- © 2024 Podchaser, Inc.
- Privacy Policy
- Terms of Service
- Contact Us